Covered recipient · General Payments record
GEORGE R BLUMENSCHEIN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$1,426.11
7 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $1,000.00 | 1 |
| Food and Beverage | $411.95 | 5 |
| Education | $14.16 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $1,017.17 | 2 |
| E.R. Squibb & Sons, L.L.C. | $300.00 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $97.34 | 2 |
| EMD Serono, Inc. | $11.60 | 1 |
Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GEORGE R BLUMENSCHEIN
NPI 1346334125 · CMS profile ID 288092
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346334125?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GEORGE R BLUMENSCHEIN, NPI 1346334125, CMS profile ID 288092. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346334125?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). GEORGE R BLUMENSCHEIN, NPI 1346334125, CMS profile ID 288092. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346334125?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- GEORGE R BLUMENSCHEIN, NPI 1346334125, CMS profile ID 288092, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1346334125?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
7 matching records · $1,426.11 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–7 of 7.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $150.00 | 12/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 708430645 | CMS |
| E.R. Squibb & Sons, L.L.C. | $150.00 | 12/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 708430649 | CMS |
| Merck Sharp & Dohme Corporation | $17.17 | 11/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695828735 | CMS |
| Merck Sharp & Dohme Corporation | $1,000.00 | 07/26/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695717145 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $83.18 | 06/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700451451 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.16 | 05/14/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700451449 | CMS |
| EMD Serono, Inc. | $11.60 | 05/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703005159 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $730.63 | 2 |
| PY2025 | Principal investigator | $826,291.13 | 39 |
| PY2024 | Recipient | $1,170.09 | 3 |
| PY2024 | Principal investigator | $765,367.11 | 23 |
| PY2023 | Principal investigator | $220,292.88 | 22 |
| PY2022 | Principal investigator | $222,960.12 | 18 |
| PY2021 | Principal investigator | $1,840,171.85 | 42 |
| PY2020 | Principal investigator | $805,658.52 | 8 |
| PY2019 | Recipient | $886.00 | 1 |
| PY2019 | Principal investigator | $1,441,336.92 | 8 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
42 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $27,238.71 | 12/31/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase II Clinical Trial of Single Agent Pembrolizumab MK-3475 in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma HNSCC Who Have Failed Platinum and Cetuximab | No dispute reported | 06/30/2026 | 848743981 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,488.14 | 12/16/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | DS1062-A-U202 | No dispute reported | 06/30/2026 | 835066757 |
| Principal investigator 1 | Amgen Inc. | $567.46 | 12/08/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | AMG 160_RR PSMA+ NSCLC_20180273 | No dispute reported | 06/30/2026 | 830987025 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $56,281.25 | 12/03/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 3 Randomized Double-blind Multicenter Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 826464567 |
| Principal investigator 1 | BeiGene, Ltd. | $60,142.00 | 11/23/2021 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | ISR-CL-BGB290-NonBGNE-0012 | No dispute reported | 06/30/2026 | 843875607 |
| Principal investigator 1 | Kite Pharma, Inc. | $25,212.00 | 11/17/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573889 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $14,320.14 | 11/10/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | DS1062-A-U202 | No dispute reported | 06/30/2026 | 835066501 |
| Principal investigator 1 | BeiGene, Ltd. | $1,250.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876047 |
| Principal investigator 1 | BeiGene, Ltd. | $29,000.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876049 |
| Principal investigator 1 | BeiGene, Ltd. | $1,000.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876051 |
| Principal investigator 1 | BeiGene, Ltd. | $3,750.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876053 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876055 |
| Principal investigator 1 | BeiGene, Ltd. | $6,250.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876057 |
| Principal investigator 1 | BeiGene, Ltd. | $8,750.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876059 |
| Principal investigator 1 | BeiGene, Ltd. | $8,750.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876073 |
| Principal investigator 1 | BeiGene, Ltd. | $6,250.00 | 10/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 843876075 |
| Principal investigator 1 | Amgen Inc. | $388.14 | 09/10/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | AMG 160_RR PSMA+ NSCLC_20180273 | No dispute reported | 06/30/2026 | 830978209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,279.39 | 08/26/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | DS1062-A-J101 | No dispute reported | 06/30/2026 | 835063647 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,168,688.54 | 08/26/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE I DOSE ESCALATION AND BIOMARKER STUDY OF LDK378 IN COMBINATION WITH EVEROLIMUS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH AN EXPANSION IN TNBC AND NSCLC CHARACTERIZED BY ABNORMALITIES IN ANAPLASTIC LYMPHOMA KINASE ALK EXPRESSION | No dispute reported | 06/30/2026 | 800618227 |
| Principal investigator 1 | Kite Pharma, Inc. | $16,808.00 | 08/23/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573885 |
| Principal investigator 1 | BeiGene, Ltd. | $22,500.00 | 08/04/2021 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | UCSF_PNOC017 | No dispute reported | 06/30/2026 | 843876609 |
| Principal investigator 1 | Kite Pharma, Inc. | $4,202.00 | 07/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573881 |
| Principal investigator 1 | Kite Pharma, Inc. | $2,000.00 | 07/02/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,750.00 | 06/24/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 793091145 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,031.25 | 06/24/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 793091147 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,750.00 | 06/24/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 793091149 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,250.00 | 06/24/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 793091151 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,115.00 | 06/23/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573873 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53,531.25 | 06/03/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | DS1062-A-U202 | No dispute reported | 06/30/2026 | 835062871 |
| Principal investigator 1 | Kite Pharma, Inc. | $25,212.00 | 05/19/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573869 |
| Principal investigator 1 | Amgen Inc. | $1,455.74 | 04/27/2021 | Non-covered Recipient Entity UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | AMG 160_RR PSMA+ NSCLC_20180273 | No dispute reported | 06/30/2026 | 830978207 |
| Principal investigator 1 | Kite Pharma, Inc. | $21,010.00 | 04/27/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573865 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $38,775.00 | 04/09/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) | No dispute reported | 06/30/2026 | 819882299 |
| Principal investigator 1 | BeiGene, Ltd. | $45,000.00 | 03/23/2021 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | UCSF_PNOC017 | No dispute reported | 06/30/2026 | 843876607 |
| Principal investigator 1 | Kite Pharma, Inc. | $4,202.00 | 03/17/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573861 |
| Principal investigator 1 | Genentech, Inc. | $4,610.10 | 03/08/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | INFLAMED SOLID TUMORS PD1 TIM3 PH1 STUDY IN SOLID TUMORS | No dispute reported | 06/30/2026 | 835933331 |
| Principal investigator 1 | Kite Pharma, Inc. | $79,717.00 | 02/17/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573857 |
| Principal investigator 1 | MacroGenics, Inc. | $3,965.64 | 02/10/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | No dispute reported | 06/30/2026 | 838709941 |
| Principal investigator 1 | MacroGenics, Inc. | $1,687.51 | 02/10/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | No dispute reported | 06/30/2026 | 838709947 |
| Principal investigator 1 | MacroGenics, Inc. | $2,784.39 | 02/10/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | No dispute reported | 06/30/2026 | 838709953 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16,305.20 | 01/26/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 819882143 |
| Principal investigator 1 | Kite Pharma, Inc. | $8,404.00 | 01/20/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*02:01 Positive Subjects with metastatic or relapsed/refractory HPV Positive Cancers | No dispute reported | 06/30/2026 | 826573853 |